Hara Levy, MD, MMSc Make an Appointment Ask a Question Refer Patient Hara Levy, MD, is a pulmonologist at National Jewish Health. Dr. Levy serves as Chief of the Division of Pediatric Pulmonary Medicine. Associate Professor Head, Division of Pediatric Pulmonary Medicine Department of Pediatrics 5280 Top Doctors 2020 Previously a 5280 Top Doctor America’s Top Doctors 2015 — Castle Connolly, Medical, Ltd. Recognized in America’s Top Doctors — Castle Connolly, Inc. Best Doctors in America® 2019-2020 — Best Doctors, Inc. Recognized in Best Doctors in America® — Best Doctors, Inc. America’s Top Doctors 2020 — Castle Connolly Medical, Ltd. Email Profile Print Profile Overview Contact Info & Locations Patient Ratings & Comments Programs & Services Bronchiectasis Treatment Program Department of Pediatrics Division of Pediatric Pulmonary Medicine Primary Ciliary Dyskinesia (PCD) Program Specialties & Conditions Asthma (Pediatric) Bronchiectasis Bronchopulmonary Dysplasia Childhood Interstitial Lung Disease Chronic Cough Congenital Anomalies of the Respiratory System Cystic Fibrosis (CF) Research Areas Cystic Fibrosis (CF) Genetics & Genomics of Cystic Fibrosis Lung Disease Special Interests Combining our work with our pulmonary patients with cutting-edge laboratory technologies facilitates our ability to achieve our vision of patient-centered care for children with cystic fibrosis (CF) as well as other pediatric pulmonary diseases. We are using blood samples from patients sampled over time to generate dynamic genome-wide expression profiles with RNA quantitation/sequencing technologies. These measurements enable us to correlate clinical characteristics (such as P. aeruginosa infection and lung function) with gene expression in each unique patient. Additional molecular and cellular assays allow us to refine the mechanisms that underpin these changes in expression, and we are in the process of developing strategies to examine the expression of miRNAs and genes associated with single-nucleotide polymorphisms and/or copy-number variants. We anticipate that these investigations will highlight genes/proteins that define a patient’s clinical course and treatment response. Our clinical interests include establishing molecular definitions of disorders of the CF spectrum, such as CFTR-related diseases and CFTR-related metabolic syndrome , as well as exploring the impact of CFTR mutations on gene expression, predictors of lung-disease severity, newborn screening, and therapeutic responsiveness. Taken together, our quantitative investigations will help us to identify and characterize non-CFTR genes that may better define and predict the severity of CF lung disease and account for the phenotypic heterogeneity that challenges physicians on a daily basis. Our pursuit of large-scale, epidemiological data from clinical cohorts allows us to evaluate the effect and impact of differential gene expression and the clinical relevance of these changes over the course of each patient’s life. My laboratory performs translational research where graduate students, clinical fellows, postdoctoral fellows and faculty can work collaboratively to advance our fundamental knowledge about genetics and genomics of CF lung disease. See More View Publications News & Videos Hara Levy, MD, MMSc, to Lead National Jewish Health for Kids Pulmonary Division Education Education 2001 - 2003 Harvard Medical School, Boston, MA, MMSc 1981 - 1986 Medical College of Wisconsin, Milwaukee, WI, MD 1981 - 1986 Stanford University, Palo Alto, CA , BS and MS Residency 1992 - 1996 Medical College of Wisconsin Affiliated Hospitals, Internal Medicine and Pediatrics Fellowship 1999 - 2001 Children's Hospital, Boston, MA, Pulmonary Medicine 1997 - 2000 Harvard Medical School, Boston, MA, Pediatric Scientist Development Training Program 1996 - 1997 Children's Hospital of Philadelphia, PA, Pediatric Cardiology Awards & Recognition 2010-2015: NIH Director's Innovator Grant Awardee 2017-2019: ATS Chair Pediatric Pulmonology Planning Committee Board Certification Pediatric Pulmonary Pediatrics Professional Memberships American Thoracic Society Society for Pediatric Research Publications Levy H, Jia S, Pan A, Zhang X, Johnson K, Kaldunski M, Nugent ML, Reske M, Feliciano RA, Renda MM, Woods KA, Verbsky J, Das T, Quasney MW, Dahmer MK, Avner E, McColley S, Farrell PM, Jacob HJ, Simpson P, Hessner M. Identification of molecular signatures in cystic fibrosis using plasma-based functional genomics. Physiol Genomics. 2019;51(1):27-41. Physiolgenomics. PMID: 30540547; PMCID: PMC6383551 Ideozu, JE, Zhang X, McColley SM and Levy H. Transcriptome profiling and molecular therapeutic advances in cystic fibrosis: recent insights. Genes 2019; 10, 180; PMID: 30813620; PMCID: PMC6383551 Audrey Tluczek A, Levy H, Rock MJ, Ondoma C, and Brown RL, Impact of Intermediate Cystic Fibrosis Classification on Parents’ Perceptions of Child Vulnerability and Protectiveness. J Fam Nurs. 2019 May;25(2):287-313. doi: 10.1177/1074840719842834. Epub 2019 Apr 26. PMID: 31027440 Zhang, X, Pan A, Shuang J, Ideozu J, Woods K, Murkowski K, Hessner M, Simpson P, Levy H. Cystic fibrosis plasma induces blunted immune response associated with bacterial infection. Am J Respir Cell Mol Biol. 2019 Sep;61(3):301-311. doi: 10.1165/rcmb.2018-0114OC. PMID:30848661 Ideozu JE, Rangaraj V, Abdala-Valencia H, Zhang X, Kandpal M, Sala MA, Davuluri RV, and Levy H. Transcriptional consequences of impaired immune cell responses induced by cystic fibrosis plasma characterized via dual RNA Sequencing. BMC Med Genomics. 2019; 12: 66. Published online 2019 May 22. doi: 10.1186/s12920-019-0529-0; PMCID: PMC6532208 Academic Affiliations Associate Professor of Pediatrics Ask a Question through Patient Portal Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account Contact Information Office: 877.225.5654 Locations National Jewish Health Main Campus 1400 Jackson St. Denver, CO 80206 Patient Ratings The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes. Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey. Comments Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.